Karnataka Antibiotics AND Pharmaceuticals Limited

Karnataka Antibiotics & Pharmaceuticals Limited (KAPL) is a public sector enterprise established on March 13, 1981, in Bengaluru, Karnataka, India. The company commenced commercial production in August 1984, focusing on the manufacturing of pharmaceutical formulations such as tablets, capsules, and injectables. Initially a joint sector undertaking between Hindustan Antibiotics Limited (HAL) and the Karnataka State Industrial and Investment Development Corporation (KSIIDC), HAL's shares were transferred to the Government of India in 2009, resulting in the government holding a 59% equity stake, with KSIIDC owning the remaining 41%.

As of March 31, 2023, KAPL reported a paid-up capital of ₹13.49 crore (approximately $1.8 million USD). The company's registered office is located at Arka The Business Centre, Plot No. 37, Site No. 34/4, NTTF Main Road, Peenya Industrial Area, Bengaluru, Karnataka 560058, India. KAPL has consistently been a profit-making organization since its inception and is recognized as a Memorandum of Understanding (MoU) signing company.

KAPL operates manufacturing units in Bengaluru, Karnataka, where it produces a range of pharmaceutical formulations, including tablets, capsules, and injectables. The facilities are approved by various international regulatory bodies, ensuring compliance with global quality standards. Specific details regarding the capacities and specializations of these manufacturing plants are not publicly disclosed.

The current Managing Director of KAPL is Shri Sunil Kumar Kaimal. The company's board of directors includes:

• Shri Mahammed Ariz Ahammed
• Shri Jawaid Akhtar
• Shri Jayaram Narasimhaiah
• Shri Krishnamohanprasad
• Shri Shalini Rajneesh
• Shri Nirja Saraf
• Shri Jitendra Trivedi
• Shri Tayappa Khanapure Bhagoji
• Shri Gunjan Kinnu
• Shri Ajay Seth

These directors bring diverse expertise to the company's strategic and operational decision-making processes.

KAPL's export portfolio, valued at $3.8 million USD over 161 shipments, comprises two products across two therapeutic categories. The top five products include Ampicillin ($3.1 million USD, 2.2% market share) and Benzylpenicillin ($745,000 USD, 19.4% market share). The primary therapeutic categories are Antibiotics (80.6%) and Advanced Antibiotics (19.4%). Notably, Benzylpenicillin holds a significant market share, indicating a strong presence in the global antibiotics market.

KAPL's export data indicates a focus on markets where antibiotics are in high demand. While specific details about the company's penetration in Africa, Latin America, and Southeast Asia are not publicly available, the substantial market share of Benzylpenicillin suggests a strategic approach to regions with significant antibiotic consumption. The company's adherence to WHO-GMP standards and ISO certifications further enhance its credibility in these emerging markets.

KAPL's export strategy appears concentrated on a limited product range, with the top five products accounting for 100% of its export value. This concentration may expose the company to risks associated with market fluctuations and regulatory changes affecting these specific products. Diversifying its product portfolio and exploring new therapeutic areas could mitigate such risks and open avenues for growth in various global markets.

Specific details regarding KAPL's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's adherence to WHO-GMP standards and ISO certifications suggests a commitment to quality that aligns with international regulatory expectations.

KAPL is a WHO-GMP certified organization, indicating compliance with the World Health Organization's Good Manufacturing Practices. Additionally, the company holds ISO certifications, reflecting its commitment to quality and services in both domestic and international markets.

KAPL operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facilities are approved by various international regulatory bodies, ensuring compliance with global quality standards.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to KAPL. The company's adherence to WHO-GMP standards and ISO certifications suggests a proactive approach to maintaining compliance with international regulatory requirements.

KAPL operates in the competitive antibiotics market, with its top products being Ampicillin and Benzylpenicillin. While specific market share data for competitors in these categories is not provided, the company's significant export value and market share in Benzylpenicillin indicate a strong position. To maintain and enhance its competitive edge, KAPL may consider expanding its product portfolio and exploring new therapeutic areas.

KAPL's adherence to WHO-GMP standards and ISO certifications underscores its commitment to quality and regulatory compliance. The company's focus on antibiotics, particularly Ampicillin and Benzylpenicillin, positions it as a specialized player in the global antibiotics market. These differentiators contribute to KAPL's reputation and reliability as a pharmaceutical exporter.

KAPL's current strategic direction appears focused on the production and export of antibiotics, with a particular emphasis on Ampicillin and Benzylpenicillin. The company's adherence to international quality standards positions it well in the global market. Future strategic initiatives could include diversifying its product portfolio, exploring new therapeutic areas, and expanding into emerging markets to drive growth and mitigate risks associated with market concentration.

KAPL's export data indicates a consistent volume of shipments, with 161 shipments valued at $3.8 million USD. The company's adherence to WHO-GMP standards and ISO certifications reflects a commitment to quality and reliability. These factors suggest that KAPL is a dependable supplier in the pharmaceutical industry.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• WHO-GMP Certification: Indicates compliance with the World Health Organization's Good Manufacturing Practices. Verification can be done through the WHO's official website or by contacting KAPL directly.

• ISO Certifications: Reflects adherence to international quality standards. Verification can be conducted by reviewing KAPL's official documentation or contacting the company for certification details.

Importers should undertake the following steps to ensure a thorough evaluation of KAPL:

• Verify Certifications: Confirm the validity of WHO-GMP and ISO certifications through official channels.

• Assess Product Portfolio: Evaluate the range and quality of products offered, focusing on therapeutic areas of interest.

• Review Regulatory Compliance: Ensure that KAPL complies with relevant regulatory requirements in both domestic and international markets.

• Evaluate Financial Stability: Review financial statements and performance metrics to assess the company's financial health.

• Check References: Seek feedback from existing clients or partners to gauge reliability and service quality.

By conducting this due diligence, importers can make informed decisions and establish a reliable partnership with KAPL.